|
|
(8 intermediate revisions by the same user not shown) |
Line 2: |
Line 2: |
| | number = ML16308A221 | | | number = ML16308A221 |
| | issue date = 11/01/2016 | | | issue date = 11/01/2016 |
| | title = SHINE Medical Technologies, Inc., Submittal of Annual Financial Report | | | title = Shine Medical Technologies, Inc., Submittal of Annual Financial Report |
| | author name = Costedio J | | | author name = Costedio J |
| | author affiliation = SHINE Medical Technologies, Inc | | | author affiliation = SHINE Medical Technologies, Inc |
Line 14: |
Line 14: |
| | page count = 5 | | | page count = 5 |
| }} | | }} |
| | |
| | =Text= |
| | {{#Wiki_filter:ZJ |
| | *- Medical Technologies THIS LETTER CONTAINS PROPRIETARY INFORMATION IN ACCORDANCE WITH 10 CFR 2.390 November 1, 2016 SMT-2016-051 10 CFR 50.71 (b) |
| | U.S. Nuclear Regulatory Commission ATTN: Document Control Desk Washington, DC 20555 SHINE Medical Technologies, Inc. Submittal of Annual Financial Report SHINE Medical Technologies, Inc. (SHINE) hereby submits its annual financial report, including certified financial statements, in accordance with the requirements of 10 CFR 50.71 (b). |
| | Enclosure 1 provides the SHINE annual financial report. SHINE requests that the NRG withhold Enclosure 1, in its entirety, from public disclosure under 10 CFR 2.390. |
| | Enclosure 2 provides an affidavit supporting the proprietary treatment of the SHINE proprietary information contained in Enclosure 1, pursuant to 10 CFR 2.390. SHINE requests that the NRG withhold Enclosure 1, in its entirety, from public disclosure under 10 CFR 2.390. Upon removal of Enclosure 1, this letter is uncontrolled. |
| | If you have any questions, please contact Mr. Jeff Bartelme, Licensing Manager, at 608/210-1735. |
| | I declare under the penalty of perjury that the foregoing is true and correct. |
| | Executed on November 1, 2016. |
| | Very truly yours, |
| | ~~* |
| | A ames Costedio Vice President of Regulatory Affairs and Quality SHINE Medical Technologies, Inc. |
| | Docket No. 50-608 Enclosures cc: Administrator, Region Ill, USNRC Project Manager, USNRC Supervisor, Radioactive Materials Program, Wisconsin Division of Public Health (w/o Enclosure 1) |
| | Enclosure 1 contains proprietary information. |
| | Withhold from public disclosure under 10 CFR 2.390. |
| | Upon removal of Enclosure 1, this letter is uncontrolled. |
| | 2555 Industrial Drive I Monona, WI 53713 \ P (608) 210-1060 IF (608) 210-2504 I www.shinemed.com |
| | |
| | ENCLOSURE 1 CONTAINS PROPRIETARY INFORMATION IN ACCORDANCE WITH 10 CFR 2.390 ENCLOSURE 1 SHINE MEDICAL TECHNOLOGIES, INC. |
| | SHINE MEDICAL TECHNOLOGIES, INC. SUBMITTAL OF ANNUAL FINANCIAL REPORT SHINE MEDICAL TECHNOLOGIES, INC. |
| | FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2015 AND 2014 Enclosure 1 contains proprietary information. |
| | Withhold from public disclosure under 10 CFR 2.390. |
| | Uoon removal of Enclosure 1, this letter is uncontrolled. |
| | 26 pages follow |
| | |
| | ENCLOSURE 2 SHINE MEDICAL TECHNOLOGIES, INC. |
| | SHINE MEDICAL TECHNOLOGIES, INC. SUBMITTAL OF ANNUAL FINANCIAL REPORT AFFIDAVIT OF JAMES COSTEDIO 2 pages follow |
| | |
| | AFFIDAVIT OF JAMES COSTEDIO STATE OF WISCONSIN ) |
| | ) SS. |
| | COUNTY OF DANE ) |
| | I, James Costedio, Vice President of Regulatory Affairs and Quality of SHINE Medical Technologies, Inc. (SHINE), do hereby affirm and state: |
| | : 1. I am authorized to execute this affidavit on behalf of SHINE. I am authorized to review information submitted to or discussed with the Nuclear Regulatory Commission (NRC) and apply for the withholding of information from public disclosure. The purpose of this affidavit is to provide the information required by 10 CFR 2.390(b) in support of SHIN E's request for proprietary treatment of certain confidential commercial and financial information submitted in the annual financial report by letter SMT-2016-051 with enclosures. SHINE requests that the confidential information contained in Enclosure 1 be withheld from public disclosure in its entirety. |
| | : 2. I have knowledge of the criteria used by SHINE in designating information as sensitive, proprietary, or confidential. |
| | : 3. Pursuant to the provisions of paragraph (a)(4) of 10 CFR 2.390, the following is furnished for consideration by the NRC in determining whether the information sought to be withheld from public disclosure should be withheld. |
| | : a. The information sought to be withheld from public disclosure contained in Enclosure 1 of SMT-2016-051 is owned by SHINE, its affiliates, or third parties to whom SHINE has an obligation to maintain its confidentiality. This information is and has been held in confidence by SHINE. |
| | : b. The information sought to be protected in Enclosure 1 is not available to the public to the best of my knowledge and belief. |
| | 1 |
| | : c. The information contained in Enclosure 1 is of the type that is customarily held in confidence by SHINE, and there is a rational basis for doing so. The information that SHINE is requesting to be withheld from public disclosure includes trade secret, commercial financial information, commercial information, or information that is subject to export controls. SHINE limits access to these elements to those with a "need to know," and subject to maintaining confidentiality. |
| | : d. Public disclosure of the information in Enclosure 1 would create substantial harm to SHINE because it would reveal valuable business information regarding SHINE's competitive expectations, assumptions, processes, and current position. Its use by a competitor could substantially improve their competitive position in the design, manufacture, shipment, installation, assurance of quality, or licensing of a similar product. |
| | : e. The information contained in Enclosure 1 of SMT-2016-051 is transmitted to the NRC in confide.nee and under the provisions of 10 CFR 2.390; it is to be received in confidence by the NRC. The information is properly marked. |
| | I declare under the penalty of perjury that the foregoing is true and correct. |
| | Executed on November 1, 2016. |
| | ~ames Costedio Vice President of Regulatory Affairs and Quality SHINE Medical Technologies, Inc. |
| | 2}} |
|
---|
Category:Legal-Affidavit
MONTHYEARML24128A2182024-05-0707 May 2024 Shine Technologies, LLC, Annual Financial Report - Affidavit of Jeff Bartelme ML22271A9672022-09-28028 September 2022 Enclosure 4: Affidavit of James Costedio ML22249A1252022-08-31031 August 2022 Shine Technologies, LLC Final Safety Analysis Report - Application for an Operating License Supplement No. 30, Cover Letter ML22202A4522022-07-21021 July 2022 Enclosure 3: Shine Technologies, LLC - Affidavit of James Costedio ML22188A0582022-07-0707 July 2022 Enclosure 2 - Affidavit of James Costedio ML22188A1972022-07-0707 July 2022 Shine Technologies, LLC, Application for an Operating License Supplement No. 27 - Affidavit of James Costedio ML22164A8182022-06-13013 June 2022 Shine Technologies, LLC: Affidavit of James Costedio ML22161A9782022-06-10010 June 2022 Shine Technologies, LLC - Affidavit of James Costedio ML22032A3432022-02-0101 February 2022 Shine Technologies, LLC, Application for an Operating License Revision 1 of the Shine Response to Request for Additional Information 11-2 - Affidavit of James Costedio ML22028A2252022-01-28028 January 2022 Shine Technologies, LLC, Response to Request for Additional Information on Application for an Operating License - Affidavit ML22027A6682022-01-27027 January 2022 Shine Technologies, LLC, Operating License Application Supplement No. 16 Submittal of a Revision to the Shine Emergency Plan - Affidavit ML22027A3572022-01-27027 January 2022 Shine Technologies, LLC, Application for an Operating License Supplement No. 15 Submittal of the Phased Startup Operations Application Supplement - Affidavit of James Costedio ML22027A6722022-01-27027 January 2022 Shine Technologies, LLC Operating License Application Supplement No. 17 Submittal of a Revision to the Shine Material Control and Accounting Plan - Affidavit ML22034A6132022-01-26026 January 2022 Shine Technologies, LLC, Application for Operating License Supplement 14, Revision to Final Safety Analysis Report ML21326A2102021-11-22022 November 2021 Enclosure 4: Affidavit of James Costedio ML21272A3452021-09-29029 September 2021 Shine Medical Technologies, LLC - Affidavit of James Costedio ML21271A0772021-09-28028 September 2021 Shine Medical Technologies, LLC, Application for an Operating License Revision 1 of Shine Response to Request for Additional Information 3.4-12 - Affidavit of James Costedio ML21243A2702021-08-31031 August 2021 Enclosure 3 - Affidavit of James Costedio ML21183A1292021-07-0202 July 2021 Enclosure 3: Shine Medical Technologies, LLC, Application for an Operating License, Response to Request for Additional Information, Affidavit of James Costedio ML21011A2242020-12-15015 December 2020 Shine Medical Technologies, LLC - Operating License Application Supplement No. 6 and Response to Request for Additional Information ML20357A0892020-12-10010 December 2020 Shine Medical Technologies, LLC Operating License Application Supplement No. 5 and Response to Request for Additional Information ML20255A0272020-08-28028 August 2020 Shine Medical Technologies, LLC Operating License Application Response to Request for Additional Information and Supplement No. 3 ML20188A3012020-06-17017 June 2020 Shine Medical Technologies, LLC - Response to Request for Additional Information on Operating License Application ML20115E5422020-04-24024 April 2020 Shine Medical Technologies, LLC Submittal of Annual Financial Report ML20105A2952020-03-27027 March 2020 Shine Medical Technologies, LLC, Supplement 2 to License Application, Rev.2 to Final Safety Analysis Report ML20069B1612020-02-24024 February 2020 Transmittal of Meeting Slides for the March 4 and 5, 2020 Public Meeting Between Shine Medical Technologies, LLC and the NRC ML19339E7212019-12-0202 December 2019 Transmittal of Meeting Slides for the December 4 and 5, 2019 Public Meeting Between Shine Medical Technologies, LLC and the NRC ML19337A2752019-11-14014 November 2019 Shine Medical Technologies, LLC Supplement 1 to Final Safety Analysis Report ML19211C0442019-07-17017 July 2019 Shine Medical Technologies, LLC Application for an Operating License ML19163A1322019-06-10010 June 2019 Shine Medical Technologies, Inc. Submittal of Annual Financial Report ML19071A0562019-03-0808 March 2019 Shine Medical Technologies, Inc., Affidavit & Response to Request for Additional Information to Application for Order Approving Indirect Transfer of Control of Construction Permit Response to Request for Additional Information ML19024A3522019-01-22022 January 2019 Shine Medical Technologies - Meeting Slides for the January 31, 2019 Public Meeting Between Shine Medical Technologies, Inc. and the NRC ML18347A2152018-12-11011 December 2018 Shine Medical Technologies - Application for Order Approving Indirect Transfer of Control of Construction Permit and Conforming Administrative Construction Permit Amendment ML18166A1782018-06-13013 June 2018 Shine Medical Technologies, Inc., Submittal of Annual Financial Report ML17079A4762017-03-17017 March 2017 Shine Medical Technologies, Inc. - Request for Confirmation Re Proposed Demonstration Project ML16308A2212016-11-0101 November 2016 Shine Medical Technologies, Inc., Submittal of Annual Financial Report ML15222A2012015-07-23023 July 2015 Shine Medical Technologies, Inc. Application for Construction Permit Response to Request for Additional Information 6b.3-30 ML15131A4622015-05-0101 May 2015 Shine Medical Technologies, Inc. Application for Construction Permit, Response to Request for Additional Information ML15043A3952015-02-0606 February 2015 Shine Medical Technologies, Inc. - Application for Construction Permit - Response to Request for Additional Information ML14119A0432014-03-17017 March 2014 Affidavit for Shine Medical Technologies, Inc. Discussion Notes Associated with March 20, 2014 Meeting 2024-05-07
[Table view] Category:Letter
MONTHYEARML24128A2162024-05-0707 May 2024 Shine Technologies, LLC, Submittal of Annual Financial Report ML23229A0202023-08-17017 August 2023 Periodic Report Required by the License Conditions in Section 3.D.(1) of CPMIF-001 ML23087A2272023-05-0505 May 2023 Shine Technologies, LLC - Issuance of Amendment No. 4 to Construction Permit No. CPMIF-001 for the Receipt and Possession of Contained Special Nuclear Material ML23086C0502023-04-27027 April 2023 Shine Technologies, LLC - Letter, Environmental Assessment and Finding of No Significant Impact ML23088A3382023-04-0505 April 2023 Shine Technologies, LLC - Review of the Physical Security Plan in Support of an Operating License for a Medical Radioisotope Production Facility ML23010A1982023-02-24024 February 2023 Shine Technologies, LLC - Letter: Safety Evaluation Report for the Shine Medical Radioisotope Production Facility Operating License Application ML23048A2442023-02-17017 February 2023 Shine Technologies, LLC Request to Amend Construction Permit No. CPMIF-001 Response to Request for Additional Information ML23010A2382023-02-0303 February 2023 Shine Technologies, LLC - Individual Notice of Consideration FRN Letter ML23034A1872023-02-0303 February 2023 Shine Medical Technologies, LLC Notice of Availability of Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility (Docket Number: 50-608) ML23023A0942023-02-0202 February 2023 Notice of Availability of the Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML23023A0922023-02-0202 February 2023 Notice of Availability of the Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML23023A0862023-02-0202 February 2023 Notice of Availability of the Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML23024A1682023-02-0101 February 2023 Letter to Ken Westlake, EPA Region 5 - Issuance of Final EIS Supplement Related to the Operating License ML23024A1742023-02-0101 February 2023 Dr. Gregory Piefer, Chief Executive Officer - Issuance of Final EIS Supplement Related to the Operating License ML22287A1852023-02-0101 February 2023 Shine Technologies, LLC Regulatory Report on the Audit of Phased Startup Operations Application Supplement ML22308A2332023-01-0909 January 2023 Shine Technologies LLC - Regulatory Audit Report for Chapter 8 - Irradiation Facility and Radioisotope Production Facility Electrical Power Systems ML22347A2142023-01-0404 January 2023 Shine Technologies LLC - Regulatory Audit Report for I&C Combined Sessions ML22356A1932022-12-22022 December 2022 Shine Technologies, LLC Application for an Operating License - Response to Request for Confirmatory Information ML22347A1772022-12-14014 December 2022 Shine Technologies LLC - Regulatory Audit Report for Programmable Logic Lifecycle ML22301A1492022-12-0707 December 2022 Shine Technologies, LLC - Regulatory Audit Report for Chapter 13 - Accident Analysis and Criticality Safety ML22322A2122022-12-0202 December 2022 Shine Medical Technologies - Cybersecurity Audit Summary Report ML22322A2232022-12-0202 December 2022 Shine Medical Technologies - Fire Protection Audit Summary Report ML22348A0672022-12-0101 December 2022 Shine Technologies, LLC - Request for Confirmatory Information Related to Instrumentation and Control Systems ML22335A5722022-12-0101 December 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22292A3192022-11-30030 November 2022 Shine Medical Technologies, LLC Issuance of Order and Amendment No. 3 to Construction Permit No. CPMIF-001 ML22318A1782022-11-14014 November 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22304A1262022-10-31031 October 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22279A9512022-10-0606 October 2022 Shine Technologies, LLC Request to Amend Construction Permit No. CPMIF-001 ML22271A9632022-09-28028 September 2022 Shine Technologies, LLC Application for an Operating License Supplement No. 31 Revision to the Phased Startup Operations Application Supplement ML22263A3442022-09-20020 September 2022 Shine Technologies, LLC Application for an Operating License - Response to Request for Additional Information ML22263A0272022-09-19019 September 2022 Shine Technologies, LLC - Application for an Operating License - Response to Request for Confirmatory Information ML22220A2612022-09-12012 September 2022 Shine Technologies LLC - Regulatory Report on the Audit Chapter 14, Technical Specifications ML22251A3272022-09-0808 September 2022 Shine Technologies, LLC Application for an Operating License Revision 1 of Shine Response to Requests for Additional Information 7-38, 7-40, and 7-48 ML22249A1252022-08-31031 August 2022 Shine Technologies, LLC Final Safety Analysis Report - Application for an Operating License Supplement No. 30, Cover Letter ML22105A1102022-08-26026 August 2022 Shine Medical Technologies LLC - Request for Additional Information Related to the OGC Review of Phrase Approach ML22061A2122022-08-24024 August 2022 Shine Medical Technologies LLC - Regulatory Audit Plan for Phased Approach - Session 1 ML22213A0492022-08-0101 August 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22187A1342022-08-0101 August 2022 Shine Technologies, LLC - Update to Operating License Application Technical Review Schedule ML22206A2082022-07-27027 July 2022 Shine Medical Technologies, LLC - Request for Confirmatory Information Related to Radiation Protection Program and Waste Management ML22207A0062022-07-26026 July 2022 Shine Technologies, LLC Application for an Operating License Supplement No. 29 ML22202A4492022-07-21021 July 2022 Shine Technologies, LLC Operating License Application Supplement No. 28 - Submittal of a Revision to the Shine Emergency Plan ML22188A2412022-07-14014 July 2022 Meeting with Shine Medical Technologies, LLC (EPID No. L-2019-NEW-0004), to Discuss Development of Shine'S Cybersecurity Program for It'S Medical Isotope Production Facility ML22175A0392022-07-11011 July 2022 Letter to Reid Nelson, Achp Notice of Availability and Request for Comments on the Draft EIS Supplement Related to the Operating License for the Shine Facility ML22175A0542022-07-0808 July 2022 Letter to Gregory Piefer - Notice of Availability of the Draft EIS Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML22175A0912022-07-0808 July 2022 Notice of Availability and Request for Comments on the Draft Environmental Impact Statement Supplement Related to the Operating License for the Shine (Multiple Tribal Letters) ML22175A0772022-07-0808 July 2022 Letter to Daina Penkiunas - Notice of Availability and Request for Comments on the Draft EIS Supplement Related to the Operating License for the Shine Facility ML22175A0632022-07-0808 July 2022 Letter to Ken Westlake, EPA Region 5 - Notice of Availability and Request for Comments on the Draft EIS Supplement Related to the Operating License for the Shine Facility ML22188A1942022-07-0707 July 2022 Shine Technologies, LLC, Application for an Operating License Supplement No. 27 ML22188A0562022-07-0707 July 2022 Shine Technologies, LLC Operating License Application Supplement No. 26 Submittal of a Revision to the Shine Material Control and Accounting Plan ML22223A0662022-07-0606 July 2022 Shine Technologies, LLC, Application for an Operating License, Revision 1 of the Response to Requests for Additional Information Related to Cyber Security 2024-05-07
[Table view] |
Text
ZJ
- - Medical Technologies THIS LETTER CONTAINS PROPRIETARY INFORMATION IN ACCORDANCE WITH 10 CFR 2.390 November 1, 2016 SMT-2016-051 10 CFR 50.71 (b)
U.S. Nuclear Regulatory Commission ATTN: Document Control Desk Washington, DC 20555 SHINE Medical Technologies, Inc. Submittal of Annual Financial Report SHINE Medical Technologies, Inc. (SHINE) hereby submits its annual financial report, including certified financial statements, in accordance with the requirements of 10 CFR 50.71 (b).
Enclosure 1 provides the SHINE annual financial report. SHINE requests that the NRG withhold Enclosure 1, in its entirety, from public disclosure under 10 CFR 2.390.
Enclosure 2 provides an affidavit supporting the proprietary treatment of the SHINE proprietary information contained in Enclosure 1, pursuant to 10 CFR 2.390. SHINE requests that the NRG withhold Enclosure 1, in its entirety, from public disclosure under 10 CFR 2.390. Upon removal of Enclosure 1, this letter is uncontrolled.
If you have any questions, please contact Mr. Jeff Bartelme, Licensing Manager, at 608/210-1735.
I declare under the penalty of perjury that the foregoing is true and correct.
Executed on November 1, 2016.
Very truly yours,
~~*
A ames Costedio Vice President of Regulatory Affairs and Quality SHINE Medical Technologies, Inc.
Docket No. 50-608 Enclosures cc: Administrator, Region Ill, USNRC Project Manager, USNRC Supervisor, Radioactive Materials Program, Wisconsin Division of Public Health (w/o Enclosure 1)
Enclosure 1 contains proprietary information.
Withhold from public disclosure under 10 CFR 2.390.
Upon removal of Enclosure 1, this letter is uncontrolled.
2555 Industrial Drive I Monona, WI 53713 \ P (608) 210-1060 IF (608) 210-2504 I www.shinemed.com
ENCLOSURE 1 CONTAINS PROPRIETARY INFORMATION IN ACCORDANCE WITH 10 CFR 2.390 ENCLOSURE 1 SHINE MEDICAL TECHNOLOGIES, INC.
SHINE MEDICAL TECHNOLOGIES, INC. SUBMITTAL OF ANNUAL FINANCIAL REPORT SHINE MEDICAL TECHNOLOGIES, INC.
FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2015 AND 2014 Enclosure 1 contains proprietary information.
Withhold from public disclosure under 10 CFR 2.390.
Uoon removal of Enclosure 1, this letter is uncontrolled.
26 pages follow
ENCLOSURE 2 SHINE MEDICAL TECHNOLOGIES, INC.
SHINE MEDICAL TECHNOLOGIES, INC. SUBMITTAL OF ANNUAL FINANCIAL REPORT AFFIDAVIT OF JAMES COSTEDIO 2 pages follow
AFFIDAVIT OF JAMES COSTEDIO STATE OF WISCONSIN )
) SS.
COUNTY OF DANE )
I, James Costedio, Vice President of Regulatory Affairs and Quality of SHINE Medical Technologies, Inc. (SHINE), do hereby affirm and state:
- 1. I am authorized to execute this affidavit on behalf of SHINE. I am authorized to review information submitted to or discussed with the Nuclear Regulatory Commission (NRC) and apply for the withholding of information from public disclosure. The purpose of this affidavit is to provide the information required by 10 CFR 2.390(b) in support of SHIN E's request for proprietary treatment of certain confidential commercial and financial information submitted in the annual financial report by letter SMT-2016-051 with enclosures. SHINE requests that the confidential information contained in Enclosure 1 be withheld from public disclosure in its entirety.
- 2. I have knowledge of the criteria used by SHINE in designating information as sensitive, proprietary, or confidential.
- 3. Pursuant to the provisions of paragraph (a)(4) of 10 CFR 2.390, the following is furnished for consideration by the NRC in determining whether the information sought to be withheld from public disclosure should be withheld.
- a. The information sought to be withheld from public disclosure contained in Enclosure 1 of SMT-2016-051 is owned by SHINE, its affiliates, or third parties to whom SHINE has an obligation to maintain its confidentiality. This information is and has been held in confidence by SHINE.
- b. The information sought to be protected in Enclosure 1 is not available to the public to the best of my knowledge and belief.
1
- c. The information contained in Enclosure 1 is of the type that is customarily held in confidence by SHINE, and there is a rational basis for doing so. The information that SHINE is requesting to be withheld from public disclosure includes trade secret, commercial financial information, commercial information, or information that is subject to export controls. SHINE limits access to these elements to those with a "need to know," and subject to maintaining confidentiality.
- d. Public disclosure of the information in Enclosure 1 would create substantial harm to SHINE because it would reveal valuable business information regarding SHINE's competitive expectations, assumptions, processes, and current position. Its use by a competitor could substantially improve their competitive position in the design, manufacture, shipment, installation, assurance of quality, or licensing of a similar product.
- e. The information contained in Enclosure 1 of SMT-2016-051 is transmitted to the NRC in confide.nee and under the provisions of 10 CFR 2.390; it is to be received in confidence by the NRC. The information is properly marked.
I declare under the penalty of perjury that the foregoing is true and correct.
Executed on November 1, 2016.
~ames Costedio Vice President of Regulatory Affairs and Quality SHINE Medical Technologies, Inc.
2